KRAS and non-small cell lung carcinoma: Preclinical studies showed that ASP3082 induced degradation of KRAS G12D protein, inhibition of KRAS downstream proteins, and an apoptotic response, and exhibited potent dose-dependent antitumor activities in multiple KRAS G12D-mutated cancer models (PDAC, CRC, and NSCLC) [222].